TY - JOUR
T1 - Sharing Is Caring?
T2 - International Society for Pharmacoepidemiology Review and Recommendations for Sharing Programming Code
AU - Tazare, John
AU - Wang, Shirley V
AU - Gini, Rosa
AU - Prieto-Alhambra, Daniel
AU - Arlett, Peter
AU - Morales Leaver, Daniel R
AU - Morton, Caroline
AU - Logie, John
AU - Popovic, Jennifer
AU - Donegan, Katherine
AU - Schneeweiss, Sebastian
AU - Douglas, Ian
AU - Schultze, Anna
N1 - Publisher Copyright:
© 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
PY - 2024/9/4
Y1 - 2024/9/4
N2 - Purpose There is increasing recognition of the importance of transparency and reproducibility in scientific research. This study aimed to quantify the extent to which programming code is publicly shared in pharmacoepidemiology, and to develop a set of recommendations on this topic. Methods We conducted a literature review identifying all studies published in Pharmacoepidemiology and Drug Safety (PDS) between 2017 and 2022. Data were extracted on the frequency and types of programming code shared, and other key open science practices (clinical codelist sharing, data sharing, study preregistration, and stated use of reporting guidelines and preprinting). We developed six recommendations for investigators who choose to share code and gathered feedback from members of the International Society for Pharmacoepidemiology (ISPE). Results Programming code sharing by articles published in PDS ranged from 1.8% in 2017 to 9.5% in 2022. It was more prevalent among articles with a methodological focus, simulation studies, and papers which also shared record-level data. Conclusion Programming code sharing is rare but increasing in pharmacoepidemiology studies published in PDS. We recommend improved reporting of whether code is shared and how available code can be accessed. When sharing programming code, we recommend the use of permanent digital identifiers, appropriate licenses, and, where possible, adherence to good software practices around the provision of metadata and documentation, computational reproducibility, and data privacy.
AB - Purpose There is increasing recognition of the importance of transparency and reproducibility in scientific research. This study aimed to quantify the extent to which programming code is publicly shared in pharmacoepidemiology, and to develop a set of recommendations on this topic. Methods We conducted a literature review identifying all studies published in Pharmacoepidemiology and Drug Safety (PDS) between 2017 and 2022. Data were extracted on the frequency and types of programming code shared, and other key open science practices (clinical codelist sharing, data sharing, study preregistration, and stated use of reporting guidelines and preprinting). We developed six recommendations for investigators who choose to share code and gathered feedback from members of the International Society for Pharmacoepidemiology (ISPE). Results Programming code sharing by articles published in PDS ranged from 1.8% in 2017 to 9.5% in 2022. It was more prevalent among articles with a methodological focus, simulation studies, and papers which also shared record-level data. Conclusion Programming code sharing is rare but increasing in pharmacoepidemiology studies published in PDS. We recommend improved reporting of whether code is shared and how available code can be accessed. When sharing programming code, we recommend the use of permanent digital identifiers, appropriate licenses, and, where possible, adherence to good software practices around the provision of metadata and documentation, computational reproducibility, and data privacy.
KW - open science
KW - pharmacoepidemiology
KW - programming code sharing
KW - reproducibility
KW - transparency
UR - http://www.scopus.com/inward/record.url?scp=85203296980&partnerID=8YFLogxK
U2 - 10.1002/pds.5856
DO - 10.1002/pds.5856
M3 - Article
C2 - 39233394
AN - SCOPUS:85203296980
SN - 1053-8569
VL - 33
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
IS - 9
M1 - e5856
ER -